Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:10/5/2009

ery strong immune system, have a very potent inflammatory response, seemingly more active than in young children or older adults. Although it seems illogical, their overactive inflammatory response may put these individuals at higher risk to serious disease due to the damage it causes in trying to eliminate the virus infection.

Influenza vaccines activate immune responses in people that can last for a long time. For a vaccinated individual the vaccine induced immune response can act quickly to stop the reproduction of the virus, limit the spread of the virus and quickly prevent significant virus damage. Currently there are two types of influenza vaccines, a live vaccine and a killed vaccine. A person receiving the Flumist live vaccine is infected with a weakened mixture of influenza viruses that cannot cause serious disease but they activate the immune response to produce T cells that make cytokines to activate T cells and other white blood cells that will kill influenza infected cells and stimulate antibody production. Other influenza vaccines use inactivated virus or the H1 and N1 proteins of the virus to immunize a person and produce only antibodies against the virus. These vaccines take approximately 10 days to produce a protective immune response.

CEL-SCI's DENDRITIC H1N1 TREATMENT

CEL-SCI's dendritic H1N1 treatment, being developed as a treatment for H1N1 hospitalized patients, utilizes the unique LEAPS vaccine technology to convert an individual's white blood cells into cells targeted to killing influenza. The treatment is based on CEL-SCI's L.E.A.P.S. technology. LEAPS vaccines are small proteins that combine a piece of an influenza protein with a small activator protein. The combined protein activates the dendritic cell, a white blood - cell, which presents the influenza protein to the T cell and then tells that T cell with a focused, controlled amount of cytokine, to grow and make the cytokines ne
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
2. CEL-SCI Expands H1N1 Flu Virus Work
3. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
4. CEL-SCI Posts New Corporate Presentation to Website
5. CEL-SCI Corporation Releases Letter to Shareholders
6. CEL-SCI Corporation Releases Letter to Shareholders
7. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
8. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
9. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Corporation Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... and ensure faster access to client ... ... DATA ), a technology and services company focused on global,eClinical solutions ... efficiency for end-users with the,DATATRAK eClinical(TM) 2008 Q1 Release., ...
... needle-free vaccine,platform that elicits a robust immune response ... been awarded a U.S. patent. The University of,Michigan ... from the,university, licenses the patent and its associated ... nanoemulsion,technology, have elicited a dramatic immune response in ...
Cached Medicine Technology:DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0 2DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0 3DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0 4DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0 5New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity 2New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity 3
(Date:4/20/2014)... Calif. A single type of cell in the ... of invasive bladder cancer, according to researchers at the ... in mice, is the first to pinpoint the normal ... cancers. It,s also the first to show that most ... just one cell, and explains why many human bladder ...
(Date:4/18/2014)... The Gerontologist reports that among older ... decrease in anxiety about death and increases in life ... In particular, listening to gospel music is associated with ... in sense of control. , These associations are similar ... of both low- and high-socioeconomic status. , The article, ...
(Date:4/18/2014)... worst memories? How did it make you feel? According ... personal experience, such as how sad you were or ... especially when you can,t stop thinking about it. ... the context of the memories, rather than how you ... alleviate the negative effects of these memories, a new ...
(Date:4/18/2014)... (April 18, 2014) ― A new study in the ... patterns in health-related Google searches reveals a recurring pattern ... , Investigators from San Diego State University, ... Monday Campaigns, analyzed "healthy" Google searches (searches that included ... diet") originating in the U.S. from 2005 to 2012. ...
(Date:4/17/2014)... The presence of chronic inflammation in benign ... prostate cancer, and this association was found even ... according to a study published in Cancer ... the American Association for Cancer Research. , An ... participants of the placebo arm of the Prostate ...
Breaking Medicine News(10 mins):Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Religious music brings benefit to seniors' mental health 2Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... Shareholders Approve Dividend Payment of EUR 0.40 per ... ended,the financial year 2007 with a positive result. In ... EBITDA) of,EUR181.6m. For the first quarter of the current ... 18.2% to EUR 239.1m, with a 20.4%,increase in operating ...
... 23 MDNG, a publication that,reaches nearly a ... online discussion that will provide physicians an opportunity,to ... whose unique,practice model has made him a household ... 28, 2008, at 8:00 p.m. EDT at, http://www.mdnglive.com/chat/JayParkinson ...
... EXTON, Pa., May 23 Kensey Nash Corporation,(Nasdaq: ... 12th Annual Spring,Investor Conference at the Grand Hyatt New ... 2008., Douglas G. Evans, Kensey Nash,s COO, will ... To hear the live,webcast of the Kensey Nash presentation ...
... 40,000 Americans each year , , FRIDAY, May 23 (HealthDay ... lungs that,s fatal within a few years of diagnosis ... researchers say daily use of the drug pirfenidone improved ... with the illness, called idiopathic pulmonary fibrosis (IPF). , ...
... HARBIN, China, May 23 /Xinhua-Prnewswire-FirstCall/ -- China Sky ... marketer and,distributor of pharmaceutical, medicinal and diagnostic products ... been approved for listing on,the American Stock Exchange ... under the symbol "CSY". This approval is contingent ...
... "American Right To Life is,offering attorney James Bopp ... "if he can name a single justice on the ... unborn child has a,right to life, whether in a ... after Bopp and NRTL refused President Ronald,Reagan,s offer to ...
Cached Medicine News:Health News:Gerresheimer Continues Expansion Course 2Health News:MDNG Offers Free Online Discussion With Maverick Physician Jay Parkinson, M.D. 2Health News:Kensey Nash to Participate in the Friedman Billings Ramsey 12th Annual Spring Investor Conference 2Health News:Drug for Deadly Lung Disease Shows Promise 2Health News:Drug for Deadly Lung Disease Shows Promise 3Health News:China Sky One Medical, Inc. Approved for Listing on the American Stock Exchange 2Health News:$10,000 Offer to National RTL From American RTL to Name 'One' Pro-Life Justice 2
... A lower cost alternative to Equalizers, the ... transfers between two different vessel configurations. With the ... can be quickly and easily adjusted for test ... Ergonomic Design for Unparalleled Comfort Pick ...
... Expandable Tip System A lower cost alternative ... to perform multi-sample transfers between two different vessel ... knob, tip spacing can be quickly and easily ... 96 well plates. Ergonomic Design for Unparalleled ...
... Well Plate Capability The Equalizer 384 ... Equalizerexpandable and equal tip spacing, choice of two ... In addition, this model allows you to evenly ... and accessing many gels and for use with ...
... With 384 Well Plate Capability The ... the original Equalizerexpandable and equal tip spacing, choice ... calibration capabilities. In addition, this model allows you ... for loading and accessing many gels and for ...
Medicine Products: